AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04165148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saint-Antoine Pain Questionnaire (QDSA)
Description: The patient evaluates her pain using an QDSA questionnaire on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with QDSA questionnaire) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an QDSA questionnaire.
Study NCT04165148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post-operative questionnaire
Description: The patient will fill in the antalgic intake record and the patient booklet for the collection of medical consumptions from her discharge from the hospital and during the month following the surgery.
Study NCT04165148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: post-operative questionnaire
Description: The patient will fill in the antalgic intake record and the patient booklet for the collection of medical consumptions from her discharge from the hospital and during the month following the surgery.
Study NCT02700464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder EpiCheck Urine Test
Description: The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer
Study NCT00630331 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose (0.5 mL) of phosphate buffered solution.
Study NCT02402855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of a prepaid payment card
Description: Delivery of a prepaid payment card credited according to consultations attended
Study NCT02402855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview with a sociologist
Description: For a sub-group of 40 womens
Study NCT02402855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Study NCT01785173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton-tipped applicator gauze pledgetting
Description: In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
Study NCT00561860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine Arm
Description: Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
Study NCT04619160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: TCI 4 µg/mL start until BIS-value of 50
Study NCT04619160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: start 1 MAC, until BIS-value of 50
Study NCT02490020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Study NCT00095940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally
Study NCT00095940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00095940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00095940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00095940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study NCT00095940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Correlative studies
Study NCT02700464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy and pathology
Description: Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy
Study NCT00711464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil (M1, M2, M4)
Description: modafinil 100, 200, and 400 mg oral dose
Study NCT00711464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: modafinil (M1, M2, M4)
Description: modafinil 100, 200, and 400 mg oral dose
Study NCT00983684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrabeam
Description: A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
Study NCT00983684 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative radiotherapy
Description: All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
Study NCT03192696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atherectomy Catheter
Description: Treatment of restenotic lesions within stents previously placed within the artery.
Study NCT00539266 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow derived mononuclear cells
Description: 40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells
Study NCT00539266 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 IM injections (calf muscle) of placebo suspension
Study NCT02464709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
Study NCT02464709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl 5-aminolevulinate
Description: A 0,25mm-thick layer of MAL (methyl 5-aminolevulinate, Metvix®) light sensitizer cream is applied on one randomized treatment side of face.
Study NCT03202576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Bridle
Description: Nasal bridle placement and securement of the tube. Instead of taping the tube to the patient's face, nose or upper lip the bridle is a device whereby a magnetic retrieval system is attached to 1/8 inch umbilical tape which is inserted via the nares, looping around the nasal septum and vomer bone and ending with both ends of the bridle (umbilical tape) secured together and to the feeding tube just outside the nose.
Study NCT01376102 — intervention group
Intervention type: DRUG
Intervention: BONVIVA(ibandronate) injection
Description: Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study NCT03575715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
Study NCT00804115 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Latanoprost with Pilocarpine vs Timolol or Cosopt
Description: Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
Study NCT00821678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Outreach for PTSD
Description: The intervention involves an off-site PTSD care team (tele-psychiatrist, tele-psychologist, tele-pharmacist, and tele-nurse care manager) and uses telemedicine technologies (telephone, interactive video and electronically shared medical records). A dedicated nurse telephone care manager educates/activates patients, identifies preferences, overcomes treatment barriers, monitors symptoms, side-effects and adherence, identifies psychiatric comorbidities, and encourages patient self-management. Tele-pharmacists provide medication management by phone. Tele-psychologists provide Cognitive Processing Therapy via interactive video. Tele-psychiatrists supervise the off-site care team as well as conduct consultations and provide medication management via interactive video.
Study NCT03222466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-created PEM
Description: A co-created PEM has been designed in collaboration with patients.
Study NCT03006861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3.5 mL/d topical creatine
Study NCT03006861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3.5 mL/d topical creatine
Study NCT03006861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3.5 mL/d topical placebo
Study NCT03006861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3.5 mL/d topical placebo
Study NCT03006861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 21 g/d Oral creatine
Study NCT03006861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 21 g/d oral placebo
Study NCT01386333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
Study NCT01386333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxytocin
Description: Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
Study NCT01221935 — intervention group
Intervention type: OTHER
Intervention: Pristiq first-line treatment charts
Description: 300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
Study NCT01221935 — intervention group
Intervention type: OTHER
Intervention: Pristiq second-line treatment charts
Description: 800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
Study NCT01386333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Mist
Description: Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts
Study NCT04817501 — intervention group
Intervention type: OTHER
Intervention: Taking 5 ml of venous blood at different time intervals
Study NCT04817501 — intervention group
Intervention type: OTHER
Intervention: Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any
Study NCT01750892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH for Independence
Description: REACH for Independence is a transition and self-care skill-building peer support group led by a social worker. It is comprised of two 2.5-hour group sessions where participants participate in activities designed to teach self-care, self-advocacy and improve transition to adulthood skills.
Study NCT01750892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Consult
Description: The transition consult is a 1-on-1 visit with an MD and social worker. At the consults, participants will receive individualized information related to their unique medical and psychosocial needs and support related to issues relevant to their gaining healthcare independence and finding an adult doctor, such as accommodations, transportation, insurance and finances. After the consult, this group will have access to a transition coordinator who can help with any transition-related problems that may occur.
Study NCT01750892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Materials
Description: The Study Materials include a Care Binder, a Resource list, an Adult Doctor List and a Wallet Card. The Care Binder is an organizational tool to help patients with special healthcare needs manage and track important information related to their health and medical care. The Resource list has information about important community resources. The Adult Doctor List provides information about finding an adult primary care provider. The Wallet Card is a sheet for tracking important medical and personal information.
Study NCT01750892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Materials
Description: The Study Materials include a Care Binder, a Resource list, an Adult Doctor List and a Wallet Card. The Care Binder is an organizational tool to help patients with special healthcare needs manage and track important information related to their health and medical care. The Resource list has information about important community resources. The Adult Doctor List provides information about finding an adult primary care provider. The Wallet Card is a sheet for tracking important medical and personal information.
Study NCT05246332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grounding
Description: The investigators used a grounding wire and a sham grounding wire to create grounding and sham-grounding groups. Participants sat on a chair barefoot in contact with the grounding mat for 30 minutes. The participants were blinded to the grounding because they did not know which one had a grounding effect according to the exterior of the mat.
Study NCT05246332 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Grounding
Description: The investigators used a grounding wire and a sham grounding wire to create grounding and sham-grounding groups. Participants sat on a chair barefoot in contact with the grounding mat for 30 minutes. The participants were blinded to the grounding because they did not know which one had a grounding effect according to the exterior of the mat.
Study NCT03591081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intellin smart phone application
Description: This feasibility study will explore if creating an electronic platform Intellin smart phone application can promote and support timely self-referral for individuals with a recently healed DFU. It will explore the software applications acceptance and ease of use for patients.
Study NCT00784797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mifepristone and misopristol
Description: 200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses
Study NCT00784797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mifepristone and oxytocin
Description: 200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)
Study NCT00112905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT00112905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT02583334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (30# acupuncture needle)
Description: Acupuncture will be applied by inserting acupuncture needle into acupoints (LI4, LI11, LR3, ST36, SP6, GB34)
Study NCT02583334 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Streitberger device will be applied by onto acupoints (LI4, LI11, LR3, ST36, SP6, GB34). The device will not really insert the blunt needle into skin but let the participants feel like real acupuncture (Lancet 1998; 352: 364-365.).
Study NCT04391959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 Active
Description: AZR-MD-001 is an active ophthalmic ointment
Study NCT04391959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 Vehicle
Description: AZR-MD-001 is a vehicle ophthalmic ointment
Study NCT01231997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: 100mg Single Oral Dose of
Study NCT01937455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-PG9DP
Description: 4x10\^12 vg administered intramuscularly
Study NCT01937455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-PG9DP
Description: 4x10\^13 vg administered intramuscularly
Study NCT01937455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-PG9DP
Description: 8x10\^13 vg administered intramuscularly
Study NCT01937455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-PG9DP
Description: 1.2x10\^14 vg administered intramuscularly
Study NCT03351777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PR022
Description: Topical Gel
Study NCT03351777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR022
Description: Topical Gel
Study NCT03194984 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrogen peroxide 35%
Description: The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
Study NCT03194984 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrogen peroxide 38%
Description: The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
Study NCT03412773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg once every 3 weeks (Q3W), intravenous dosing (IV)
Study NCT03412773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg twice daily (BID), oral dosing
Study NCT03705793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Irrigation
Description: Participants will undergo an 8-week treatment course that includes nasal saline irrigation with mometasone powder and placebo nasal spray.
Study NCT03705793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Nasal Spray
Description: Participants will undergo an 8-week treatment course that includes placebo saline irrigation with mometasone nasal spray.
Study NCT02641509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI during polypectomy
Description: NBI to perform the polipectomy
Study NCT02641509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: no NBI during polypectomy
Description: no NBI to perform the polypectomy
Study NCT02672085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP infiltraiton
Description: Two time with 1 month interval, PRP will be extracted from own blood's patients with Regenlab® extraction kit, and injected into supraspinatus interstitial lesion.
Study NCT02672085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needling
Description: Two time with 1 month interval, saline water will be injected into supraspinatus interstitial lesion.
Study NCT06133660 — intervention group
Intervention type: PROCEDURE
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy and Silicone oil removal to distinguish subjects
Study NCT01869647 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultra low dose CT scan
Description: Ultra low dose CT scan
Study NCT01221935 — intervention group
Intervention type: OTHER
Intervention: SNRI or SSRI first-line treatment charts
Description: 800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
Study NCT01221935 — intervention group
Intervention type: OTHER
Intervention: SNRI or SSRI second-line treatment charts
Description: 800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
Study NCT02881567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: High yield formulation
Study NCT01869647 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Regular CT or Low Dose CT scan
Description: Regular CT or Low Dose CT scan
Study NCT01869647 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No imaging
Description: No imaging
Study NCT01390909 — intervention group
Intervention type: DRUG
Intervention: Anti-epileptic drug (AED)
Description: Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
Study NCT02456714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Study NCT00610090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UniFit AAA Stent Graft
Description: Endovascular repair of Abdominal Aortic Aneurysms